Cash Equivalents - Cartesian Therapeutics Inc (NASDAQ:RNAC) - Alpha Spread

Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 16.54 USD 5.82% Market Closed
Market Cap: 353.6m USD
Have any thoughts about
Cartesian Therapeutics Inc?
Write Note

Cartesian Therapeutics Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cartesian Therapeutics Inc
Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Cartesian Therapeutics Inc
NASDAQ:RNAC
Cash Equivalents
$87.2m
CAGR 3-Years
-11%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$13.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$2.8B
CAGR 3-Years
-17%
CAGR 5-Years
-24%
CAGR 10-Years
-11%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9.3B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
8%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$4.6B
CAGR 3-Years
-9%
CAGR 5-Years
7%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$1.9B
CAGR 3-Years
-2%
CAGR 5-Years
13%
CAGR 10-Years
12%

See Also

What is Cartesian Therapeutics Inc's Cash Equivalents?
Cash Equivalents
87.2m USD

Based on the financial report for Jun 30, 2024, Cartesian Therapeutics Inc's Cash Equivalents amounts to 87.2m USD.

What is Cartesian Therapeutics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
24%

Over the last year, the Cash Equivalents growth was -22%. The average annual Cash Equivalents growth rates for Cartesian Therapeutics Inc have been -11% over the past three years , 24% over the past five years .

Back to Top